(NEOG) Neogen - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6404911066
NEOG: Diagnostic, Test, Kits, Pharmaceuticals, Vaccines, Insecticides
Neogen Corporation (NASDAQ: NEOG) is a leader in the development, manufacturing, and marketing of products and services focused on food and animal safety. Operating through two distinct segments—Food Safety and Animal Safety—the company serves a diverse range of industries globally. The Food Safety segment specializes in diagnostic solutions to detect contaminants in food and animal feed, including pathogens, allergens, and residues. Their product portfolio includes the AccuPoint Advanced rapid sanitation test and genomics-based diagnostic technology, catering to sectors such as meat, poultry, dairy, and healthcare. This segments solutions are integral to ensuring safety across the food supply chain.
The Animal Safety segment offers a comprehensive suite of products, including veterinary instruments, pharmaceuticals, and diagnostic tools, distributed through veterinarians, retailers, and livestock producers. This segment serves various markets, from companion animals to livestock, providing essential health and safety solutions. With a market cap of approximately $2.3 billion, Neogens financials show a forward P/E of 16 and a P/S ratio of 2.54, indicating a scalable business model. The companys recurring revenue streams and global presence underscore its strategic position in the health care supplies industry, making it a significant player for investors seeking stability and growth in the safety and diagnostics sector.
Additional Sources for NEOG Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
NEOG Stock Overview
Market Cap in USD | 2,146m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Health Care Supplies |
IPO / Inception | 1989-08-23 |
NEOG Stock Ratings
Growth 5y | -76.3% |
Fundamental | -24.1% |
Dividend | 0.0% |
Rel. Strength Industry | -41.2 |
Analysts | 4.33/5 |
Fair Price Momentum | 6.83 USD |
Fair Price DCF | - |
NEOG Dividends
No Dividends PaidNEOG Growth Ratios
Growth Correlation 3m | -90.7% |
Growth Correlation 12m | -45.7% |
Growth Correlation 5y | -82.6% |
CAGR 5y | -19.84% |
CAGR/Max DD 5y | -0.24 |
Sharpe Ratio 12m | -1.05 |
Alpha | -53.97 |
Beta | 1.40 |
Volatility | 49.80% |
Current Volume | 3105.5k |
Average Volume 20d | 2375.7k |
As of March 15, 2025, the stock is trading at USD 9.05 with a total of 3,105,509 shares traded.
Over the past week, the price has changed by -12.98%, over one month by -7.93%, over three months by -23.63% and over the past year by -40.66%.
Neither. Based on ValueRay Fundamental Analyses, Neogen is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -24.12 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NEOG as of March 2025 is 6.83. This means that NEOG is currently overvalued and has a potential downside of -24.53%.
Neogen has received a consensus analysts rating of 4.33. Therefor, it is recommend to buy NEOG.
- Strong Buy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, NEOG Neogen will be worth about 7.5 in March 2026. The stock is currently trading at 9.05. This means that the stock has a potential downside of -16.8%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 14 | 54.7% |
Analysts Target Price | 15.8 | 74% |
ValueRay Target Price | 7.5 | -16.8% |